First Pre-Revenue Biotech IPO Rejection By 'China’s Nasdaq'

More Focus On Innovation?

 
• By Dexter Jie Yan

The STAR Market of the Shanghai Stock Exchange has called a halt to the potentially third-largest biotech IPO this year in an apparent deterrent to the in-licensing model.

In-licensing model faces barriers
in-licensing model becomes apparent barrier to biotech IPOs in China. • Source: Alamy

More from China

More from Focus On Asia